Bristol-Myers Squibb's Kenneth Weg Elected to Fox Chase Cancer Center Board
PHILADELPHIA (May 7, 1998) -- Kenneth E. Weg, executive vice president of Bristol-Myers Squibb Company in Princeton, N.J., has been elected to the board of directors of Fox Chase Cancer Center. Bristol-Myers Squibb is a diversified worldwide health and personal care products company. Weg also serves on the company's board of directors and is president of its Worldwide Medicines Group.
As a member of Fox Chase Cancer Center's board of directors, Weg will help promote the Center's new $38 million campaign to add 11 research programs related to cancer prevention and build a new facility to house the planned Research Institute for Cancer Prevention at Fox Chase. Weg serves on the board's finance committee.
Weg has more than 30 years of experience in the health-care industry and has played a key role in the management of Bristol-Myers Squibb for over a decade. He began his career with the company in 1969 when he joined its International Division and subsequently held positions of increased responsibility in various international markets and regions. He joined the Squibb Corporation in 1987 and after the 1989 merger forming the Bristol-Myers Squibb Company, he held key executive positions with the Pharmaceutical Group.
Before joining Bristol-Myers Squibb, Weg held sales, marketing and planning positions with Merck, Sharp & Dohme International. He earned his B.A. degree from Dartmouth College and his M.B.A. degree in finance from Columbia University "Both laboratory and clinical research are vital not only in treating cancer patients more effectively but in learning to prevent many cases of cancer in people with special risks," said Weg. "Fox Chase is one of the country's leading comprehensive cancer centers and reflects the innovative advances in cancer therapies that are under way throughout the health-care community. I'm pleased with this opportunity to work closely with the Center's scientific staff and medical personnel."
Weg is a trustee of both the Princeton Medical Center and the Foundation for New Jersey Public Broadcasting. He is also a member of the Philadelphia Museum of Art's corporate executive committee.
Fox Chase is one of 32 National Cancer Institute-designated comprehensive cancer centers. Its activities include basic and clinical research; prevention, detection and treatment of cancer; and community outreach programs.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.